Aktis Oncology, Inc.

Aktis Oncology, Inc. is a clinical-stage biopharmaceutical company that develops targeted radiopharmaceuticals to treat solid tumors. The company utilizes a proprietary miniprotein radioconjugate platform to bind radioisotope payloads, such as alpha-emitting actinium-225, to cancer cells while rapidly clearing normal tissues. Its lead product candidate, [225Ac]Ac-AKY-1189, targets Nectin-4-expressing cancers, including urothelial cancer and other solid tumors such as lung, breast, colorectal, and cervical malignancies. Another candidate in development, [225Ac]Ac-AKY-2519, targets B7-H3-expressing tumors such as prostate and lung cancers. The company also maintains early-stage discovery programs and a research collaboration with Eli Lilly. Its target patients are individuals diagnosed with solid tumor cancers expressing these specific tumor markers.

The company is based in the United States, with corporate headquarters located in Boston, Massachusetts. Its operations include a multi-site clinical trial network across the United States, along with research and development facilities. Aktis Oncology works with domestic and international suppliers and contract manufacturers for isotope sourcing and drug manufacturing.

Summary of the business section of Aktis Oncology's latest annual report, written by StockData.